Speece Thorson Capital Group’s Labcorp LH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.7M Sell
43,843
-1,282
-3% -$347K 2.66% 21
2025
Q4
$11.3M Sell
45,125
-2,743
-6% -$729K 2.45% 23
2025
Q3
$13.7M Sell
47,868
-580
-1% -$155K 2.75% 18
2025
Q2
$12.7M Buy
48,448
+1,013
+2% +$247K 2.59% 25
2025
Q1
$11M Sell
47,435
-852
-2% -$207K 2.27% 28
2024
Q4
$11.1M Sell
48,287
-336
-0.7% -$77.1K 2.18% 28
2024
Q3
$10.9M Sell
48,623
-174
-0.4% -$38.2K 2.01% 31
2024
Q2
$9.93M Sell
48,797
-4,954
-9% -$1.01M 2.03% 29
2024
Q1
$11.7M Sell
53,751
-685
-1% -$151K 2.27% 28
2023
Q4
$12.4M Sell
54,436
-9,493
-15% -$1.99M 2.54% 23
2023
Q3
$12.9M Sell
63,929
-11,031
-15% -$2.33M 2.83% 14
2023
Q2
$15.5M Sell
74,960
-781
-1% -$152K 3.18% 9
2023
Q1
$14.9M Sell
75,741
-861
-1% -$177K 3.15% 9
2022
Q4
$15.5M Buy
76,602
+8,956
+13% +$1.75M 3.33% 7
2022
Q3
$11.9M Buy
67,646
+2,113
+3% +$433K 2.72% 16
2022
Q2
$13.2M Buy
65,533
+13,173
+25% +$2.81M 3.11% 9
2022
Q1
$11.9M Sell
52,360
-10,136
-16% -$2.38M 2.54% 17
2021
Q4
$16.9M Buy
62,496
+208
+0.3% +$51.5K 3.22% 14
2021
Q3
$15.1M Sell
62,288
-15,900
-20% -$4.01M 3.15% 12
2021
Q2
$18.5M Sell
78,188
-387
-0.5% -$88.2K 3.87% 6
2021
Q1
$17.2M Sell
78,575
-451
-0.6% -$90.5K 3.62% 9
2020
Q4
$13.8M Sell
79,026
-13,144
-14% -$2.27M 3.29% 12
2020
Q3
$14.9M Buy
92,170
+448
+0.5% +$71K 3.95% 6
2020
Q2
$13.1M Sell
91,722
-1,104
-1% -$153K 3.77% 6
2020
Q1
$10.1M Sell
92,826
-1,478
-2% -$213K 3.47% 11
2019
Q4
$13.7M Sell
94,304
-732
-0.8% -$106K 3.55% 11
2019
Q3
$13.7M Sell
95,036
-2,305
-2% -$336K 3.67% 7
2019
Q2
$14.5M Sell
97,341
-296
-0.3% -$41.3K 3.85% 5
2019
Q1
$12.8M Sell
97,637
-2,735
-3% -$337K 3.53% 7
2018
Q4
$10.9M Buy
100,372
+22,413
+29% +$3M 3.26% 10
2018
Q3
$11.6M Sell
77,959
-12,911
-14% -$1.96M 2.7% 13
2018
Q2
$14M Sell
90,870
-2,496
-3% -$377K 2.95% 14
2018
Q1
$13M Sell
93,366
-6,506
-7% -$956K 2.75% 17
2017
Q4
$13.7M Sell
99,872
-735
-0.7% -$97.1K 2.72% 17
2017
Q3
$13M Sell
100,607
-17,378
-15% -$2.32M 2.72% 17
2017
Q2
$15.6M Buy
117,985
+565
+0.5% +$69.2K 3.26% 12
2017
Q1
$14.5M Buy
117,420
+3,226
+3% +$382K 3.06% 15
2016
Q4
$12.6M Sell
114,194
-3,813
-3% -$424K 2.82% 16
2016
Q3
$13.9M Sell
118,007
-24,003
-17% -$2.83M 2.99% 12
2016
Q2
$15.9M Buy
142,010
+1,949
+1% +$210K 3.45% 5
2016
Q1
$14.1M Buy
140,061
+2,055
+1% +$197K 3.16% 9
2015
Q4
$14.7M Buy
138,006
+809
+0.6% +$83.5K 3.57% 8
2015
Q3
$12.8M Sell
137,197
-408
-0.3% -$42.2K 3.18% 11
2015
Q2
$14.3M Buy
137,605
+12,607
+10% +$1.31M 3.45% 9
2015
Q1
$13.5M Sell
124,998
-32,197
-20% -$3.31M 3.18% 12
2014
Q4
$14.6M Sell
157,195
-2,083
-1% -$184K 3.55% 11
2014
Q3
$13.9M Sell
159,278
-5,145
-3% -$465K 3.56% 11
2014
Q2
$14.5M Sell
164,423
-1,409
-0.8% -$122K 3.68% 8
2014
Q1
$14M Sell
165,832
-23
-0% -$1.83K 3.69% 7
2013
Q4
$13M Buy
165,855
+2,930
+2% +$250K 3.45% 6
2013
Q3
$13.9M Sell
162,925
-2,235
-1% -$188K 3.84% 5
2013
Q2
$14.2M Buy
+165,160
New +$13.7M 4.14% 3

Other funds holding LH

Speece Thorson Capital Group's LH Position: Q1 2026 in Review

Speece Thorson Capital Group reduced its Labcorp (LH) stake by 2.8% in Q1 2026, selling an estimated $347K and leaving 43,843 shares worth $11.7M. The position accounts for 2.66% of the portfolio, ranked #21.

Speece Thorson Capital Group first reported a position in LH in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.5M in Q2 2021. 1,031 funds tracked by Wall St. Rank hold LH as of Q1 2026.

  • Speece Thorson Capital Group held 43,843 shares of Labcorp worth $11.7M as of Q1 2026.
  • Speece Thorson Capital Group sold 1,282 Labcorp shares in Q1 2026, an estimated $347K.
  • Labcorp made up 2.66% of Speece Thorson Capital Group's portfolio in Q1 2026, its #21 holding.
  • Speece Thorson Capital Group first reported a position in Labcorp in Q2 2013 and has held it in 52 quarters since.
  • Speece Thorson Capital Group's Labcorp position peaked at $18.5M in Q2 2021.
  • 1,031 funds tracked by Wall St. Rank held Labcorp as of Q1 2026.

Based on Speece Thorson Capital Group's 13F filing for Q1 2026, filed 29 Apr 2026.